- Home
- EPM vs PLX Comparison
EPM vs PLX Comparison
Compare EPM & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPM
- PLX
- Stock Information
- Founded
- EPM 2003
- PLX 1993
- Country
- EPM United States
- PLX Israel
- Employees
- EPM N/A
- PLX N/A
- Industry
- EPM Oil & Gas Production
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPM Energy
- PLX Health Care
- Exchange
- EPM Nasdaq
- PLX Nasdaq
- Market Cap
- EPM 169.0M
- PLX 160.2M
- IPO Year
- EPM 1996
- PLX 1998
- Fundamental
- Price
- EPM $5.60
- PLX $2.33
- Analyst Decision
- EPM Strong Buy
- PLX
- Analyst Count
- EPM 1
- PLX 0
- Target Price
- EPM $8.25
- PLX N/A
- AVG Volume (30 Days)
- EPM 201.5K
- PLX 553.9K
- Earning Date
- EPM 02-04-2025
- PLX 03-13-2025
- Dividend Yield
- EPM 8.59%
- PLX N/A
- EPS Growth
- EPM N/A
- PLX N/A
- EPS
- EPM 0.14
- PLX N/A
- Revenue
- EPM $87,172,000.00
- PLX $45,667,000.00
- Revenue This Year
- EPM $7.51
- PLX N/A
- Revenue Next Year
- EPM N/A
- PLX $90.00
- P/E Ratio
- EPM $39.97
- PLX N/A
- Revenue Growth
- EPM N/A
- PLX N/A
- 52 Week Low
- EPM $4.59
- PLX $0.82
- 52 Week High
- EPM $6.29
- PLX $2.36
- Technical
- Relative Strength Index (RSI)
- EPM 62.56
- PLX 78.72
- Support Level
- EPM $5.25
- PLX $2.11
- Resistance Level
- EPM $5.46
- PLX $2.36
- Average True Range (ATR)
- EPM 0.13
- PLX 0.12
- MACD
- EPM 0.06
- PLX 0.00
- Stochastic Oscillator
- EPM 93.22
- PLX 94.23
About EPM Evolution Petroleum Corporation Inc.
Evolution Petroleum Corp is an independent oil and gas company operating in the United States. It is engaged predominantly in the acquisition, exploitation, and development of properties for the production of crude oil and natural gas, onshore in the United States. The company's revenues are generated from its crude oil, natural gas, and NGL production from the Jonah Field in Sublette County, Wyoming; the Williston Basin in North Dakota; the Barnett Shale located in North Texas; the Hamilton Dome Field in Wyoming; and the Delhi Field in Northeast Louisiana.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.